Red blood cell MCV
There was no evidence of a difference in change in MCV from enrolment (adjusted for baseline) by treatment arm. However, as expected, different trends were observed by zidovudine use (Table Change in red blood cell mean cell volume to week 96, by treatment arm and ZDV exposure. (i) Children starting second‐line ART who had zidovudine in the 14 days prior to randomization and whose initial trial regimen did not contain zidovudine; (ii) children starting second‐line ART who did not have zidovudine in the 14 days prior to randomization and whose initial trial regimen contained zidovudine; (iii) children starting first‐line whose initial first‐line regimen did not contain zidovudine; and (iv) children starting second‐line whose initial second‐line regimen did not contain zidovudine and who did not have zidovudine in the 14 days prior to treatment switch. Participants in ODYSSEY A whose initial regimen included zidovudine are not included due to small numbers (